Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
 
I am taking CAMPATH
I Am Considering Campath
I Am a Caregiver
 
Understanding CLL
Resources and Tools
CamCareTM Assistance Program
Nursing Assistance
Meet Our CamCareTM Nurses
 
   Home  |  Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only
Print | Text Size:

Resources and Tools

 

Meet Our CamCare™ Nurses

Sandy, RN, OCN, has 24 years of experience in the field of Oncology. Since becoming an Oncology Certified Nurse in 1988, Sandy has held nursing positions at Swedish Hospital Medical Center, affiliated with the Fred Hutchinson Cancer Research Center in Seattle, Washington, and Stanford University Medical Center, Stanford, California, caring for Hematology and Bone Marrow Transplant patients. She recently coauthored an article, "Treatment of Chronic Lymphocytic Leukemia with Alemtuzumab: A Review for Nurses," published in The Oncology Nursing Forum. She has been with the CamCare program since its inception in 2001. Sandy says that the most satisfying thing about her job is getting to know her patients, teaching them about their disease process, and assisting in managing therapy-related side effects they experience.

Vicki, RN, OCN, received her nursing degree from Solano Community College in 1982. She earned a Bachelor of Science in Biology from California State University, San Francisco in 1976. Vicki has been an oncology nurse since 1984 and initially received her Oncology Certification in 1986. She has spent the majority of her nursing career at Stanford University Hospital specializing in the care of patients undergoing treatment for leukemia and bone marrow transplant. Vicki joined the CamCare team in June of 2001. Although Vicki enjoys all aspects of oncology nursing, her greatest joy comes from educating patients and developing relationships with both patients and their caregivers.

Betsy, RN, BSN, OCN, received her Bachelor of Science degree in nursing from the University of Akron in Akron, Ohio in 1985. She later became an Oncology Certified Nurse in 1995. Her professional experience includes clinical and research positions at the National Cancer Institute of Health, and she was a Program Coordinator in the Hematology and Oncology Department at Louisiana State University Medical Center in Shreveport, Louisiana. Since May of 2001 she has been part of the CamCare team educating healthcare professionals and patients on Campath administration. Betsy has found assisting patients during treatment and involving herself in their lives to be the most rewarding parts of her job.

Rosalie, RN, MSN, CNS, FNP has over 25 years of experience as a nurse: 20 years in oncology at different settings and specialties: Oncologic Emergency, Neurosurgery, Breast, Melanoma, XRT, Cancer Prevention and Early Detection, BMT and Ambulatory Treatment Center (treats >10,000 patients monthly) — coverage includes: management of cancer treatment/chemo acute adverse effects of standard chemotherapy and phase I trials. Rosalie also manages anticoagulation in oncology. She has published multiple articles on Cancer-related fatigue, febrile neutropenia and triage in oncologic emergencies and wrote a book chapter on Triage in an Oncologic Emergency Textbook. Rosalie joined the CamCare Nursing staff in 2005.

To reach a CamCare™ nurse, call 1-800-473-5832. Click here to learn more about 24-hour CamCareTM nursing assistance.

Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).